Recombinant HSV-2 Vaccine Vector for Cross-Serotype Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) are ineffective, with recent clinical trials of sub-unit formulations failing to provide significant protection, and existing attenuated viruses have limited therapeutic applications and no efficacy in preventing infections.
Innovation Solution
A recombinant HSV-2 virus with a deletion of the HSV-2 glycoprotein D-encoding gene is developed, which can express HSV-1 or other surface glycoproteins on its lipid bilayer, used to create a vaccine that elicits an immune response and provides protection against HSV-1 and HSV-2 infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sub-unit vaccine formulations using viral glycoproteins are used, then systemic neutralizing antibodies are induced, but significant protection against HSV-1, HSV-2 or HIV is not achieved
Solution Approach 1:
The patent uses a recombinant HSV-2 virus as an intermediary vector to deliver HSV-1 glycoprotein D (gD) antigens. This viral vector mediates the presentation of foreign antigens in a natural infection context, triggering more effective immune responses compared to sub-unit formulations. The recombinant virus acts as a carrier that presents the antigen in a biologically relevant form, resolving the contradiction between simplicity and efficacy.
Solution Approach 2:
The recombinant HSV-2 vaccine vector serves multiple functions: it acts as both the delivery vehicle and the antigen source. By engineering HSV-2 to express HSV-1 gD, the system provides cross-protection against both HSV-1 and HSV-2 infections simultaneously. This multi-functionality approach overcomes the limitation of sub-unit vaccines that required separate formulations for different serotypes.
2Reliability
If attenuated viruses are used for therapeutic applications, then frequency of recurrences is reduced, but efficacy in preventing infections is not shown
Solution Approach 1:
The patent extracts the glycoprotein D-encoding gene (Us6) from the HSV-2 genome to create a deletion mutant. This extraction of the virulence factor creates an attenuated virus that is safe for use as a vaccine while retaining the ability to express foreign antigens. The deleted Us6 gene prevents the virus from causing severe disease, allowing it to be used prophylactically rather than just therapeutically.
Solution Approach 2:
The vaccine induces immune responses before actual infection occurs, creating pre-existing immunity. The recombinant HSV-2 vaccine primes the immune system with HSV-1 gD antigens and HSV-2 structural proteins, so that when challenge with wild-type HSV-1 or HSV-2 occurs, the immune system is already prepared to neutralize the virus immediately, preventing infection rather than just treating recurrence.
3Reliability
If HSV-2 gD subunit vaccine is used, then partial protection against HSV-1 is provided, but no protection against HSV-2 is achieved
Solution Approach 1:
The recombinant HSV-2 vaccine vector expresses both HSV-1 gD (the heterologous antigen) and HSV-2 structural proteins (gB, gC, gE, gI, gK, gL, gM, gN, gO, gP, gQ, gR, gS, gT, gU, gV, gW, gX, gY, gZ). This dual antigen presentation provides universal protection against both HSV-1 and HSV-2 serotypes simultaneously, overcoming the limitation of gD subunit vaccines that only provided partial cross-protection.
Solution Approach 2:
The vaccine creates a composite viral particle that combines HSV-2 structural proteins with HSV-1 gD antigens. This composite structure presents both HSV-1 and HSV-2 epitopes in a single vaccine formulation, enabling broad serotype coverage. The hybrid nature of the viral particle allows it to be recognized by immune systems as both HSV-1 and HSV-2, providing cross-protective immunity.
Data Source
Figure 1
Figure 2A~2D
Figure 3A~3C
AI summary
Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such, and methods of use thereof are each provided.